SCHEMBL18579569

SCHEMBL18579569

Fc1ccc(CCn2cnc(-c3ccccn3)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5B Q9UGL1 9/20 0.62
▸ KDM5A P29375 4/20 0.62
▸ KDM6B O15054 3/20 0.54
▸ KDM4C Q9H3R0 3/20 0.46
▸ KDM4A O75164 2/20 0.46
▸ FLT3 P36888 1/20 0.45
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ KDM2B Q8NHM5 3/20 0.43
▸ HTR1A P08908 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ ADRA2C P18825 1/20 0.41
▸ DRD1 P21728 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ DRD5 P21918 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ HTR7 P34969 1/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ DRD3 P35462 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18579255 0.86 KDM5B (0.61) KDM5BKDM5AKDM4CKDM4AFLT3
SCHEMBL18579762 0.81 KDM5A (0.67) KDM5BKDM5AKDM4CKDM4ANPC1
SCHEMBL19101682 0.78 KDM5B (0.66) KDM5BKDM5AKDM6BKDM4CKDM4A
SCHEMBL16033515 0.77 KDM5A (1.00) KDM5BKDM5AKDM4CKDM4AKDM2B
SCHEMBL7101565 0.76 KDM4E (0.47) KDM5BKDM5AKDM4CKDM4ANPC1
SCHEMBL16034316 0.76 KDM5A (0.57) KDM5BKDM5AKDM4CKDM4AFLT3
SCHEMBL26209086 0.75 KDM6B (0.62) KDM5BKDM5AKDM6BKDM4CKDM4A
SCHEMBL18579812 0.75 KDM4C (0.67) KDM5BKDM5AKDM4CKDM4AFLT3
SCHEMBL18579672 0.75 KDM4C (0.67) KDM5BKDM5AKDM4CKDM4AKDM2B
SCHEMBL18579507 0.75 KDM4C (0.65) KDM5BKDM5AKDM6BKDM4CKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963441-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-05-08 — — US disclosed
US-20170066739-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE PHARMACEUTICALS INC (US) 2017-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066739-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM3B KDM5B 10/4885KDM5A 8/4885KDM6B 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback